PMC3420486_01
Computed tomography (CT) scan of the chest shows a mass opacity involving the right hilar lymph node.
CRIM.PULMONOLOGY2011-812972.001.jpg
PMC3420486_01_CRIM.PULMONOLOGY2011-812972.001.jpg
fig1
A chest X-ray demonstrated mass opacity at the right hilar area, and a computed tomography (CT) scan of the chest and the abdomen showed mass opacity involving the right hilar lymph node without any signs of liver metastasis (Figure 1). A baseline blood test revealed that the electrolyte levels and renal function were normal.
The course of chest X-ray images and transaminase levels during gefitinib and erlotinib treatments.
CRIM.PULMONOLOGY2011-812972.002.jpg
PMC3420486_01_CRIM.PULMONOLOGY2011-812972.002.jpg
fig2
Gefitinib treatment was reintroduced with an intermittent schedule after the patient's transaminase levels normalized; however, the enzyme levels rose again when 250 mg of gefitinib was administered every two days (Figure 2). Therefore, the treatment was switched to erlotinib (150 mg once daily) 159 days after the initiation of gefitinib, and the tumor decreased in size, as determined by chest X-ray (Figure 2).